Fluticasone Propionate
Product Images NDC 53002-2294

Product Visual Gallery

This gallery contains 15 technical images submitted to the FDA as part of the official labeling for Fluticasone Propionate (NDC 53002-2294). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Rpk Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Fluticasone Propionate Chemical Structure (Fluticasonepropionatehfa Spl Graphic 01)

FDA Label Image

Figure 1. A 12-week Clinical Trial In Subjects Aged 12 Years And Older Inadequately Controlled On Bronchodilators Alone: Mean Percent Change From Baseline In Fev1 Prior To Am Dose (trial 1) (Fluticasonepropionatehfa Spl Graphic 02)

FDA Label Image

Figure 2. A 12-week Clinical Trial In Subjects Aged 12 Years And Older Already Receiving Daily Inhaled Corticosteroids: Mean Percent Change From Baseline In Fev1 Prior To Am Dose (trial 2) (Fluticasonepropionatehfa Spl Graphic 03)

This appears to be a chart displaying the percent change from baseline in FEV (forced expiratory volume) for various treatments. The treatments listed are a placebo, Fluticasone Propionate HFA (at various doses), and it appears there are 12 weeks of data collected for each treatment. The results appear to have been graphed over time, with endpoints at weeks 1, 5, 6, 7, 8, 9, 10, 11, and 12.*

FDA Label Image

Figure 3. A 16-week Clinical Trial In Subjects Aged 12 Years And Older Requiring Chronic Oral Prednisone Therapy: Change In Maintenance Prednisone Dose (Fluticasonepropionatehfa Spl Graphic 04)

This appears to be a chart or table displaying percentages of subjects in relation to dose and reduction in dose for Fluticasone Propionate HFA. The chart shows that 5% of subjects had an increase in dose, while 38% had a reduction in dose. There is also information regarding the reduction in dose percentage of subjects when compared to a placebo group. Without additional context or information, it is difficult to provide a more detailed description of the text.*

FDA Label Image

Figure A (Fluticasonepropionatehfa Spl Graphic 05)

This is a description of a metal canister with a dark orange plastic actuator and a mouthpiece, which has a peach cap.*

FDA Label Image

Figure B (Fluticasonepropionatehfa Spl Graphic 06)

FDA Label Image

Figure C (Fluticasonepropionatehfa Spl Graphic 07)

FDA Label Image

Figure D (Fluticasonepropionatehfa Spl Graphic 08)

FDA Label Image

Figure E (Fluticasonepropionatehfa Spl Graphic 09)

FDA Label Image

Figure F (Fluticasonepropionatehfa Spl Graphic 10)

This is a breathing exercise instruction, telling the reader to exhale as much air as possible.*

FDA Label Image

Figure G (Fluticasonepropionatehfa Spl Graphic 11)

FDA Label Image

Figure H (Fluticasonepropionatehfa Spl Graphic 12)

FDA Label Image

Figure I (Fluticasonepropionatehfa Spl Graphic 13)

FDA Label Image

Figure J (Fluticasonepropionatehfa Spl Graphic 14)

FDA Label Image

Label Image (Lbl530022294)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.